CellCarta, a global provider of precision medicine laboratory services, and a portfolio company ion private equity firm Arsenal Capital, has acquired Biogazelle (Biogazelle), a specialist in genomic testing solutions.
Located in Ghent (Belgium), Biogazelle develops and deploys high-end digital PCR (dPCR), quantitative PCR (qPCR) and RNASeq assays for its pharmaceutical and biotech industry clients.
